Navigation Links
FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
Date:3/11/2008

our scientists have designed into the compound, yielding a clinically differentiated product in this market."

"This important regulatory milestone enables Arisaph to begin the process of demonstrating the compound's promise in the clinic," commented Alexander "Zan" Fleming, M.D., clinical/regulatory consultant to Arisaph, President and Chief Executive Officer of Kinexum and former head of diabetes review at FDA. "As an endocrinologist, the unprecedented preclinical efficacy of ARI-2243 is very intriguing and the potential benefits for patients are very exciting. I look forward to working with Arisaph to demonstrate the differentiated efficacy and safety of ARI-2243 in the clinic."

As part of the IND submission, Arisaph completed comprehensive nonclinical safety pharmacology and toxicology studies, including 28 day toxicology studies in rats and primates. The results show that ARI-2243 has a favorable safety pharmacology profile and has a high therapeutic index. Based on the preclinical efficacy of ARI-2243, the company believes that low doses will produce superior blood glucose lowering compared with other DPP-4 inhibitors.

Arisaph designed ARI-2243 as a once a day, orally active, smart DPP-4 inhibitor that is highly potent and functionally selective. In vitro, kinetic studies show that ARI-2243 has an extremely high affinity (Ki of 27 picomolar) for the DPP-4 enzyme and drug dissociation from the enzyme is very slow. Such kinetics confer potency and long activity. During OGTT in normal mice, ARI- 2243 was 250 times more potent than sitagliptin and maximally lowered blood glucose by 88%. Additionally, in ZDF rats, an animal model that develops overt diabetes, ARI-2243 significantly reduced hemoglobin A1c (HbA1c) by 2.5% versus no effect with vildagliptin.(3)

In addition to the compelling preclinical efficacy, ARI-2243 is functionally selective through a smart, "soft drug" inactivation process. Specifically, ARI-2243 binds rapidly and tig
'/>"/>

SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 The global ... 49.12 billion by 2020, growing at a CAGR of ... report by Grand View Research, Inc. Monitoring services is ... from 2014 to 2020.      (Logo: ... with rising incidences of chronic diseases such as cancer, ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... 27, 2015 Biosimilars are not generics ... U.S. Food and Drug Administration (FDA) for recognizing ... its draft guidance issued today. The FDA,s draft ... distinguishable names, calling for biological products to bear ... This proposal reflects the agency,s thinking that "there ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... -- At this very moment, FIRMOO is being heatedly discussed ... eyeglasses from FIRMOO are being delivered to various countries of ... so many eyeglasses wearers? In this brand new year of ... platforms, is giving away thousands of free eyeglasses every day ...
... 6, 2012 ViroPharma Incorporated (NASDAQ: ... HALO ) today announced the presentation of positive ... Cinryze® (C1 esterase inhibitor [human]) in combination with ... using Halozyme,s recombinant human hyaluronidase enzyme (rHuPH20), in ...
Cached Medicine Technology:Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 2Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 2ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 4ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 5ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 6ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 7ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 8
(Date:8/30/2015)... ... 30, 2015 , ... Natural Rest contains a unique mixture of vitamins and ... remedies, which help to improve mood disorders and anxiety. Like all other Creative Medical ... the field of regenerative medicine conducted by Dr. Amit Patel of the University of ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... Executive Assistant to CEO Mitch Gould for Nutritional Products International. Through all ... Kathleen graduated from Florida State University with a Bachelor of Science in ...
(Date:8/29/2015)... ... 2015 , ... On September 30, 2015, the Career and Transfer Center (CTC) ... Maricopa Community Colleges , will be hosting a Job Expo to provide a ... opportunities. , The Expo has expanded to much more than just a typical job ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... of two inventors from Miller Place, N.Y. "I specialize in manual therapy, and ... In addition, it can be used for additional muscle dysfunction throughout the body." ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., ... His mission is to increase acceptance of the chiropractic field in the military. All ... debilitate them. Although Chiropractic was made available to the VA program over a ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... respiratory problems, CDC report says , , WEDNESDAY, Oct. 22 (HealthDay ... has soared 18 percent in the last decade, with an ... the condition, a new federal report says. , In 2007, ... reported to have had a food or digestive allergy in ...
... $1.60 per share in the third quarter of 2008 -- Medical membership grew by 63,000 ... exceeded 35.3 million at September 30, 2008 -- Benefit expense ratio declined by ... ... increased ...
... 22 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... medical devices worldwide today announced that it will,report ... September 30,2008, after the U.S. market closes on ... conference call at 8:00 a.m. on November,11, 2008 ...
... cost-pressured, limited pipeline biotech and pharmaceutical companies, the market for ... 2012. , ... San Jose, Calif. ... challenges in the form of increasing competition in generic markets, ...
... mother and gluten-free cook/author Theresa Santandrea-Cull - is a collection of ... and wheat products. , ... (PRWEB) October 22, 2008 ... latest recipe book "No Wheat? No Way!" she included ...
... health, how to diagnose disease early and other tips to prolong dogs, lives ... ... cause of death in dogs, affecting more than 10 percent of all dogs ... to this issue - www.yourdogsheart.com - is designed to educate pet ...
Cached Medicine News:Health News:Food Allergies Up 18% Among U.S. Children 2Health News:WellPoint Reports Third Quarter 2008 Results 2Health News:WellPoint Reports Third Quarter 2008 Results 3Health News:WellPoint Reports Third Quarter 2008 Results 4Health News:WellPoint Reports Third Quarter 2008 Results 5Health News:WellPoint Reports Third Quarter 2008 Results 6Health News:WellPoint Reports Third Quarter 2008 Results 7Health News:WellPoint Reports Third Quarter 2008 Results 8Health News:WellPoint Reports Third Quarter 2008 Results 9Health News:WellPoint Reports Third Quarter 2008 Results 10Health News:WellPoint Reports Third Quarter 2008 Results 11Health News:WellPoint Reports Third Quarter 2008 Results 12Health News:WellPoint Reports Third Quarter 2008 Results 13Health News:WellPoint Reports Third Quarter 2008 Results 14Health News:WellPoint Reports Third Quarter 2008 Results 15Health News:WellPoint Reports Third Quarter 2008 Results 16Health News:WellPoint Reports Third Quarter 2008 Results 17Health News:WellPoint Reports Third Quarter 2008 Results 18Health News:WellPoint Reports Third Quarter 2008 Results 19Health News:WellPoint Reports Third Quarter 2008 Results 20Health News:WellPoint Reports Third Quarter 2008 Results 21Health News:WellPoint Reports Third Quarter 2008 Results 22Health News:WellPoint Reports Third Quarter 2008 Results 23Health News:WellPoint Reports Third Quarter 2008 Results 24Health News:WellPoint Reports Third Quarter 2008 Results 25Health News:Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008 2Health News:Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc. 3Health News:Now Available Online, Beneficial Recipe Book Offers Wheat-Free, Gluten-Free Options for Healthy Living 2Health News:New Web Site Devoted to Canine Heart Disease - A Leading Cause of Death in Dogs 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: